慢性B型肝炎ウイルス臨床試験分析 2025：EMA、PDMA、FDA承認、臨床試験、治療法、薬剤、NDA承認、IND、作用機序、投与経路（DelveInsight）

DelveInsight's "Chronic Hepatitis B Virus Pipeline Insight 2025" report delivers in-depth information on over 50 companies and more than 55 pipeline drugs in the Chronic Hepatitis B Virus treatment landscape. It encompasses profiles of pipeline drugs for Chronic Hepatitis B Virus, including those in clinical and nonclinical phases. Additionally, it evaluates therapies by product category, development stage, administration method, and molecular structure. It also highlights discontinued pipeline products in this field.

Explore the newest medications and therapeutic approaches in the Chronic Hepatitis B Virus Pipeline. Check out DelveInsight's thorough report right away! @ Chronic Hepatitis B Virus Pipeline Outlook - https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Key Insights from the Chronic Hepatitis B Virus Pipeline Report

• In April 2025, Vir Biotechnology Inc. revealed a phase 1b/2 platform trial design to test the safety and effectiveness of experimental candidates and their combinations as possible therapies for adults with chronic hepatitis B virus infection.
• In April 2025, GlaxoSmithKline disclosed that a study will evaluate the safety, effectiveness, and immune response after sequential administration of GlaxoSmithKline's (GSK) ASO compound (GSK3228836) and CHB-TI (GSK3528869A) in individuals aged 18 to 65 who are stable on NA therapy for CHB. The goal is to measure the effectiveness of sequential treatment and assess its benefits over GSK3228836 alone in CHB patients on NAs. Furthermore, the study will examine the impact of varying GSK3228836 treatment lengths (12 or 24 weeks) before starting GSK3528869A.
• DelveInsight's Chronic Hepatitis B Virus pipeline report illustrates a vibrant field with over 50 active organizations developing more than 55 pipeline therapies for Chronic Hepatitis B Virus management.
• Leading Chronic Hepatitis B Virus Companies include Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm, and others.
• Promising Chronic Hepatitis B Virus Pipeline Therapies include Peginterferon Alfacon, Daplusiran/Tomligisiran Dose Level 1, Bepirovirsen, Tenofovir disoproxil fumarate (TDF), VIR-2218, PEG-IFNα, and others.

Keep up with the most current pipeline developments for Chronic Hepatitis B Virus. Gain knowledge on clinical trials, novel therapies, and prominent companies through DelveInsight @ Chronic Hepatitis B Virus Treatment Drugs - https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Chronic Hepatitis B Virus Emerging Drugs Profile Pradefovir: Ligand Pharmaceuticals Pradefovir is an oral liver-directed prodrug of the HBV DNA polymerase/reverse transcriptase inhibitor adefovir, aimed at treating hepatitis B virus (HBV) infection. The medication utilizes Ligand's HepDirect technology. It is presently in Phase III development for Chronic Hepatitis B.

RG6346: Dicerna Pharmaceuticals RG6346 is an experimental GalXCTM RNAi therapeutic in partnership with Roche for chronic HBV infection. RG6346 uses RNA interference to specifically reduce genes essential for HBV messenger RNA production and viral entry into liver cells. Preclinical studies showed over 99.9% decrease in circulating HBsAg in HBV-infected mouse models. In contrast to existing treatments that usually suppress the virus long-term, RG6346 could offer a functional cure for those with chronic HBV. Dicerna is running a Phase II trial of RG6346 in adults with chronic HBV infection.

The Chronic Hepatitis B Virus Pipeline Report Offers Insights into

• The report furnishes comprehensive details on firms creating therapies for Chronic Hepatitis B Virus, including the total therapies each company is advancing.
• It reviews various therapeutic candidates divided into early, mid, and late development stages for Chronic Hepatitis B Virus treatment.
• Chronic Hepatitis B Virus Companies are engaged in targeted therapy development, with active and inactive (dormant or halted) projects.
• Chronic Hepatitis B Virus Drugs in progress, categorized by development phase, administration route, target receptor, monotherapy or combination, distinct mechanisms of action, and molecular type.
• In-depth examination of partnerships (corporate-corporate and corporate-academic), licensing deals, and funding details for advancing the Chronic Hepatitis B Virus market.

Discover innovative therapies and clinical trials in the Chronic Hepatitis B Virus Pipeline. Obtain DelveInsight's detailed report immediately! @ New Chronic Hepatitis B Virus Drugs - https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Chronic Hepatitis B Virus Companies Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm, and others.

Chronic Hepatitis B Virus Infection pipeline report assesses pipeline drugs by Route of Administration. Products are grouped under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Chronic Hepatitis B Virus Products are grouped under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Reveal the future of Chronic Hepatitis B Virus Treatment. Understand new drugs, pipeline progress, and major companies with DelveInsight's expert analysis @ Chronic Hepatitis B Virus Market Drivers and Barriers - https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Scope of the Chronic Hepatitis B Virus Pipeline Report

• Coverage- Global
• Chronic Hepatitis B Virus Companies- Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm, and others.
• Chronic Hepatitis B Virus Pipeline Therapies- Peginterferon Alfacon, Daplusiran/Tomligisiran Dose Level 1, Bepirovirsen, Tenofovir disoproxil fumarate (TDF), VIR-2218, PEG-IFNα, and others.
• Chronic Hepatitis B Virus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Hepatitis B Virus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest updates on Chronic Hepatitis B Virus Therapies and clinical trials. Download DelveInsight's comprehensive pipeline report now! @ Chronic Hepatitis B Virus Companies, Key Products and Unmet Needs - https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Table of Content

• Introduction
• Executive Summary
• Chronic Hepatitis B Virus Infection: Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Chronic Hepatitis B Virus Infection - DelveInsight's Analytical Perspective
• Late Stage Products (Phase III)
• Pradefovir: Ligand Pharmaceuticals
• Drug profiles in the detailed report.....
• Mid Stage Products (Phase II)
• RG6346: Dicerna Pharmaceuticals
• Drug profiles in the detailed report.....
• Early Stage Products (Phase I/II)
• Drug name: Company name
• Drug profiles in the detailed report.....
• Early Stage Products (Phase I)
• VIR-3434: Vir Biotechnology
• Drug profiles in the detailed report.....
• Preclinical Stage Products
• SBT8230: Silverback Therapeutics
• Drug profiles in the detailed report.....
• Inactive Products
• Chronic Hepatitis B Virus Infection Key Companies
• Chronic Hepatitis B Virus Infection Key Products
• Chronic Hepatitis B Virus Infection - Unmet Needs
• Chronic Hepatitis B Virus Infection - Market Drivers and Barriers
• Chronic Hepatitis B Virus Infection - Future Perspectives and Conclusion
• Chronic Hepatitis B Virus Infection Analyst Views
• Chronic Hepatitis B Virus Infection Key Companies
• Appendix

Related Reports

Chronic Hepatitis B Virus (CHB) - Epidemiology Forecast to 2034

DelveInsight’s ‘Chronic Hepatitis B Virus (CHB) - Epidemiology Forecast to 2034’ report delivers an in-depth understanding of the disease, historical and forecasted CHB epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

About Delveinsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Kanishk Kumar

Email: kkumar@delveinsight.com 

Phone: 09650213330

Address: 304 S. Jones Blvd #2432

City: Las Vegas

State: NV

Country: United States

Website: https://www.delveinsight.com/